---
document_datetime: 2025-12-17 23:12:30
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kovaltry.html
document_name: kovaltry.html
version: success
processing_time: 0.1333135
conversion_datetime: 2025-12-28 10:53:21.337838
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kovaltry

[RSS](/en/individual-human-medicine.xml/67109)

##### Authorised

This medicine is authorised for use in the European Union

octocog alfa Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kovaltry](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78655)
- [More information on Kovaltry](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Kovaltry. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kovaltry.

For practical information about using Kovaltry, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Kovaltry and what is it used for?

Kovaltry is a medicine used for the treatment and prevention of bleeding in patients with haemophilia A (an inherited bleeding disorder caused by lack of a clotting protein called factor VIII). It contains the active substance octocog alfa, which is the same as human factor VIII.

## How is Kovaltry used?

Kovaltry is available as a powder and solvent used to make a solution for injection. The injection is given into a vein over several minutes. The dose and frequency of the injections depend on whether Kovaltry is used to treat or prevent bleeding, the severity of the patient's factor VIII deficiency, the extent and location of the bleeding and the patient's condition and bodyweight.

Kovaltry can only be obtained with a prescription and treatment should be under the supervision of a doctor who has experience in the treatment of haemophilia. For further information, see the summary of product characteristics (also part of the EPAR).

## How does Kovaltry work?

Patients with haemophilia A lack factor VIII, a protein needed for normal clotting of the blood, and as a result, they bleed readily and may have problems such as bleeding into the joints, muscles and internal organs. The active substance in Kovaltry, octocog alfa, works in the body in the same way as human factor VIII. It replaces the missing factor VIII, thereby helping the blood to clot and giving temporary control of bleeding.

## What benefits of Kovaltry have been shown in studies?

The effectiveness of Kovaltry in preventing and treating bleeding has been shown in a main study involving 62 patients aged 12 years or older with severe haemophilia A who were previously treated with other factor VIII products. The number of bleeds that occurred during Kovaltry treatment was calculated as 3.8 bleeds per year on average (mostly into joints). This compared with an average of 6.9 bleeds per year before Kovaltry treatment. Comparable results were seen in patients who continued to take the medicine after completion of the initial study.

About 70% of the bleeding events that occurred were managed with a single injection of Kovaltry, and about another 15% responded to a second injection; the response was considered good or excellent in around 80% of cases. In 12 patients who required major surgery during the study, control of blood loss was also rated as good or excellent by the patients' doctors.

A second study involved 51 children under 12 years of age previously treated with other factor VIII products, who also had 3.8 bleeds per year on average during treatment with Kovaltry (mostly related to injuries). Response to treatment was considered good or excellent in about 90% of cases.

Data from a supportive study also confirmed the benefits of preventative treatment with Kovaltry in reducing the number of bleeds.

## What are the risks associated with Kovaltry?

Hypersensitivity (allergic) reactions are uncommon with Kovaltry, affecting from 1 patient in 1,000 to less than 1 patient in 100. If they occur they may include: angioedema (swelling of tissues under the skin), burning and stinging at the injection site, chills, flushing, itchy rash over the whole body, headache, hives, hypotension (low blood pressure), lethargy, nausea (feeling sick), restlessness, tachycardia (rapid heartbeat), tightness of the chest, tingling, vomiting and wheezing. In some cases these reactions can become severe.

Patients may develop antibodies to hamster or mouse proteins; the medicine must not be used in patients who are hypersensitive (allergic) to octocog alfa or to hamster or mouse proteins. There is also a risk with factor VIII medicines that some patients will develop inhibitors (antibodies) against factor VIII, causing the medicine to stop working and resulting in a loss of bleeding control.

For the full list of all side effects and restrictions with Kovaltry, see the package leaflet.

## Why is Kovaltry approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry's benefits are greater than its risks and recommended that it be approved for use in the EU. Kovaltry has been shown to be effective in both preventing and treating bleeds, including managing blood loss during surgery, and can be used in all age groups. Regarding safety, the reported effects are in line with those expected for a factor VIII product. Further evidence of effectiveness and safety in patients previously untreated with factor VIII medicines, and further data on long-term use in children should be provided by ongoing studies.

## What measures are being taken to ensure the safe and effective use of Kovaltry?

A risk management plan has been developed to ensure that Kovaltry is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kovaltry, including the appropriate precautions to be followed by healthcare professionals and patients.

Further information can be found in the .

In addition, the company that markets Kovaltry will complete studies to investigate the safety and efficacy of the medicine in patients who have not previously been treated with other factor VIII products, and to provide further evidence of the safety and efficacy of long-term treatment with Kovaltry in children.

## Other information about Kovaltry

The European Commission granted a marketing authorisation valid throughout the European Union for Kovaltry on 18 February 2016.

For more information about treatment with Kovaltry, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Kovaltry : EPAR - Summary for the public

Reference Number: EMA/235/2016

English (EN) (96.69 KB - PDF)

**First published:** 07/03/2016

**Last updated:** 07/03/2016

[View](/en/documents/overview/kovaltry-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-27)

български (BG) (104.61 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/bg/documents/overview/kovaltry-epar-summary-public_bg.pdf)

español (ES) (77.58 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/es/documents/overview/kovaltry-epar-summary-public_es.pdf)

čeština (CS) (104.73 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/cs/documents/overview/kovaltry-epar-summary-public_cs.pdf)

dansk (DA) (76.85 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/da/documents/overview/kovaltry-epar-summary-public_da.pdf)

Deutsch (DE) (79.4 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/de/documents/overview/kovaltry-epar-summary-public_de.pdf)

eesti keel (ET) (76.5 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/et/documents/overview/kovaltry-epar-summary-public_et.pdf)

ελληνικά (EL) (106.8 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/el/documents/overview/kovaltry-epar-summary-public_el.pdf)

français (FR) (78.61 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/fr/documents/overview/kovaltry-epar-summary-public_fr.pdf)

hrvatski (HR) (100.12 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/hr/documents/overview/kovaltry-epar-summary-public_hr.pdf)

italiano (IT) (76.67 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/it/documents/overview/kovaltry-epar-summary-public_it.pdf)

latviešu valoda (LV) (100.28 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/lv/documents/overview/kovaltry-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (102.34 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/lt/documents/overview/kovaltry-epar-summary-public_lt.pdf)

magyar (HU) (99.44 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/hu/documents/overview/kovaltry-epar-summary-public_hu.pdf)

Malti (MT) (106.12 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/mt/documents/overview/kovaltry-epar-summary-public_mt.pdf)

Nederlands (NL) (77.3 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/nl/documents/overview/kovaltry-epar-summary-public_nl.pdf)

polski (PL) (104.94 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/pl/documents/overview/kovaltry-epar-summary-public_pl.pdf)

português (PT) (77.8 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/pt/documents/overview/kovaltry-epar-summary-public_pt.pdf)

română (RO) (100.14 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/ro/documents/overview/kovaltry-epar-summary-public_ro.pdf)

slovenčina (SK) (103.14 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/sk/documents/overview/kovaltry-epar-summary-public_sk.pdf)

slovenščina (SL) (98.21 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/sl/documents/overview/kovaltry-epar-summary-public_sl.pdf)

Suomi (FI) (76.31 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/fi/documents/overview/kovaltry-epar-summary-public_fi.pdf)

svenska (SV) (76.99 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

07/03/2016

[View](/sv/documents/overview/kovaltry-epar-summary-public_sv.pdf)

Kovaltry : EPAR - Risk-management-plan summary

English (EN) (165.71 KB - PDF)

**First published:** 07/03/2016

**Last updated:** 25/01/2021

[View](/en/documents/rmp-summary/kovaltry-epar-risk-management-plan-summary_en.pdf)

## Product information

Kovaltry : EPAR - Product Information

English (EN) (609.69 KB - PDF)

**First published:** 07/03/2016

**Last updated:** 13/08/2025

[View](/en/documents/product-information/kovaltry-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-212)

български (BG) (682.4 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/bg/documents/product-information/kovaltry-epar-product-information_bg.pdf)

español (ES) (593.08 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/es/documents/product-information/kovaltry-epar-product-information_es.pdf)

čeština (CS) (617.91 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/cs/documents/product-information/kovaltry-epar-product-information_cs.pdf)

dansk (DA) (570.6 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/da/documents/product-information/kovaltry-epar-product-information_da.pdf)

Deutsch (DE) (644.16 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/de/documents/product-information/kovaltry-epar-product-information_de.pdf)

eesti keel (ET) (575.05 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/et/documents/product-information/kovaltry-epar-product-information_et.pdf)

ελληνικά (EL) (727.98 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/el/documents/product-information/kovaltry-epar-product-information_el.pdf)

français (FR) (628.16 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/fr/documents/product-information/kovaltry-epar-product-information_fr.pdf)

hrvatski (HR) (612.5 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/hr/documents/product-information/kovaltry-epar-product-information_hr.pdf)

íslenska (IS) (590.33 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/is/documents/product-information/kovaltry-epar-product-information_is.pdf)

italiano (IT) (630.03 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/it/documents/product-information/kovaltry-epar-product-information_it.pdf)

latviešu valoda (LV) (641.73 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/lv/documents/product-information/kovaltry-epar-product-information_lv.pdf)

lietuvių kalba (LT) (688.21 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/lt/documents/product-information/kovaltry-epar-product-information_lt.pdf)

magyar (HU) (669 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/hu/documents/product-information/kovaltry-epar-product-information_hu.pdf)

Malti (MT) (693.2 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/mt/documents/product-information/kovaltry-epar-product-information_mt.pdf)

Nederlands (NL) (622.15 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/nl/documents/product-information/kovaltry-epar-product-information_nl.pdf)

norsk (NO) (573.46 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/no/documents/product-information/kovaltry-epar-product-information_no.pdf)

polski (PL) (631.25 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/pl/documents/product-information/kovaltry-epar-product-information_pl.pdf)

português (PT) (595.35 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/pt/documents/product-information/kovaltry-epar-product-information_pt.pdf)

română (RO) (647.11 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/ro/documents/product-information/kovaltry-epar-product-information_ro.pdf)

slovenčina (SK) (657.34 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/sk/documents/product-information/kovaltry-epar-product-information_sk.pdf)

slovenščina (SL) (687.66 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/sl/documents/product-information/kovaltry-epar-product-information_sl.pdf)

Suomi (FI) (604.38 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/fi/documents/product-information/kovaltry-epar-product-information_fi.pdf)

svenska (SV) (599.91 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

13/08/2025

[View](/sv/documents/product-information/kovaltry-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000287726 13/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kovaltry : EPAR - All Authorised presentations

English (EN) (17.53 KB - PDF)

**First published:** 07/03/2016

**Last updated:** 28/01/2020

[View](/en/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-102)

български (BG) (56.34 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/bg/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_bg.pdf)

español (ES) (30.87 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/es/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_es.pdf)

čeština (CS) (45.46 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/cs/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (29.17 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/da/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.48 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/de/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.99 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/et/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (64.42 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/el/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_el.pdf)

français (FR) (30.05 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/fr/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (41.2 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/hr/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (28.59 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/is/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_is.pdf)

italiano (IT) (29.18 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/it/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.88 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/lv/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (44.58 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/lt/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (41.7 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/hu/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (44.99 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/mt/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.47 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/nl/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (27.48 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/no/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_no.pdf)

polski (PL) (44.76 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/pl/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_pl.pdf)

português (PT) (33.47 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/pt/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_pt.pdf)

română (RO) (49.44 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/ro/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (43.54 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/sk/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (35.47 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/sl/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (29.51 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/fi/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (28.57 KB - PDF)

**First published:**

07/03/2016

**Last updated:**

28/01/2020

[View](/sv/documents/all-authorised-presentations/kovaltry-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kovaltry Active substance octocog alfa International non-proprietary name (INN) or common name octocog alfa Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02BD02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups.

## Authorisation details

EMA product number EMEA/H/C/003825 Marketing authorisation holder

Bayer AG

51368 Leverkusen Germany

Opinion adopted 17/12/2015 Marketing authorisation issued 18/02/2016 Revision 15

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kovaltry : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.08 KB - PDF)

**First published:** 13/08/2025

[View](/en/documents/procedural-steps-after/kovaltry-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kovaltry : EPAR - Procedural steps taken and scientific information after authorisation (archived)

English (EN) (214.39 KB - PDF)

**First published:** 02/08/2016

**Last updated:** 26/07/2023

[View](/en/documents/procedural-steps-after/kovaltry-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf)

Kovaltry-PAM-0000281517 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2630630

English (EN) (521.08 KB - PDF)

**First published:** 10/12/2025

[View](/en/documents/variation-report/kovaltry-pam-0000281517-epar-assessment-report_en.pdf)

Kovaltry-H-C-003825-P46-009 : EPAR - Assessment report

Adopted

Reference Number: EMA/563514/2024

English (EN) (1.22 MB - PDF)

**First published:** 04/12/2024

[View](/en/documents/variation-report/kovaltry-h-c-003825-p46-009-epar-assessment-report_en.pdf)

Kovaltry-H-C-3825-A31-0004 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/763977/2017

English (EN) (219.86 KB - PDF)

**First published:** 05/12/2017

**Last updated:** 05/12/2017

[View](/en/documents/variation-report/kovaltry-h-c-3825-a31-0004-epar-assessment-report-article-31_en.pdf)

## Initial marketing authorisation documents

Kovaltry : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/40124/2016 Rev. 1

English (EN) (1.83 MB - PDF)

**First published:** 07/03/2016

**Last updated:** 09/03/2016

[View](/en/documents/assessment-report/kovaltry-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Kovaltry

Adopted

Reference Number: EMA/CHMP/774664/2015

English (EN) (68.02 KB - PDF)

**First published:** 18/12/2015

**Last updated:** 18/12/2015

[View](/en/documents/smop-initial/chmp-summary-opinion-kovaltry_en.pdf)

#### News on Kovaltry

[Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes](/en/news/factor-viii-medicines-no-clear-consistent-evidence-difference-risk-inhibitor-development-between-classes) 15/09/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 December 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-december-2015) 18/12/2015

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Kovaltry : EPAR - Product information - tracked changes

English (EN) (265.11 KB - DOCX)

**First published:** 13/08/2025

[View](/en/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-557)

български (BG) (274.16 KB - DOCX)

**First published:**

13/08/2025

[View](/bg/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_bg.docx)

español (ES) (287.2 KB - DOCX)

**First published:**

13/08/2025

[View](/es/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_es.docx)

čeština (CS) (245.53 KB - DOCX)

**First published:**

13/08/2025

[View](/cs/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (239.36 KB - DOCX)

**First published:**

13/08/2025

[View](/da/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (357.3 KB - DOCX)

**First published:**

13/08/2025

[View](/de/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (256.57 KB - DOCX)

**First published:**

13/08/2025

[View](/et/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (265.05 KB - DOCX)

**First published:**

13/08/2025

[View](/el/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_el.docx)

français (FR) (267.28 KB - DOCX)

**First published:**

13/08/2025

[View](/fr/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (261.11 KB - DOCX)

**First published:**

13/08/2025

[View](/hr/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (245.94 KB - DOCX)

**First published:**

13/08/2025

[View](/is/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_is.docx)

italiano (IT) (356.63 KB - DOCX)

**First published:**

13/08/2025

[View](/it/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (259.87 KB - DOCX)

**First published:**

13/08/2025

[View](/lv/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (336.51 KB - DOCX)

**First published:**

13/08/2025

[View](/lt/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (279.59 KB - DOCX)

**First published:**

13/08/2025

[View](/hu/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (276.94 KB - DOCX)

**First published:**

13/08/2025

[View](/mt/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (260.94 KB - DOCX)

**First published:**

13/08/2025

[View](/nl/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (249.82 KB - DOCX)

**First published:**

13/08/2025

[View](/no/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_no.docx)

polski (PL) (268 KB - DOCX)

**First published:**

13/08/2025

[View](/pl/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_pl.docx)

português (PT) (276.82 KB - DOCX)

**First published:**

13/08/2025

[View](/pt/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_pt.docx)

română (RO) (272.34 KB - DOCX)

**First published:**

13/08/2025

[View](/ro/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (262.76 KB - DOCX)

**First published:**

13/08/2025

[View](/sk/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (272.32 KB - DOCX)

**First published:**

13/08/2025

[View](/sl/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (283.96 KB - DOCX)

**First published:**

13/08/2025

[View](/fi/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (343.31 KB - DOCX)

**First published:**

13/08/2025

[View](/sv/documents/product-information-tracked-changes/kovaltry-epar-product-information-tracked-changes_sv.docx)

#### More information on Kovaltry

- [EMEA-001064-PIP01-10-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001064-pip01-10-m03)
- [Factor VIII - referral](/en/medicines/human/referrals/factor-viii)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 10/12/2025

## Share this page

[Back to top](#main-content)